Mesenchymal stromal / stem cell vesicles for immunomodulation, mitochondrial transfer, and protection of pancreatic islet cells

Extracellular vesicles from mesenchymal stromal/stem cells address the limitations of Type 1 Diabetes therapies by modulating immune responses and transferring mitochondria to protect pancreatic islets, enhancing beta-cell function and reducing the need for immunosuppression.

WO2026236374A1PCT designated stage Publication Date: 2026-11-12AION HEALTHSPAN INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026919
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current therapies for Type 1 Diabetes, such as insulin therapy and pancreatic islet transplantation, are limited by inflammation, alloimmune rejection, recurrent autoimmunity, and the need for chronic systemic immunosuppression, while existing extracellular vesicles lack coordinated immunomodulation and mitochondrial transfer to protect pancreatic islet cells from inflammatory and mitochondrial stress.

Method used

Extracellular vesicles derived from mesenchymal stromal/stem cells, particularly human umbilical cord-derived MSCs, are formulated to modulate immune responses, transfer functional mitochondria, and protect pancreatic islet cells by stimulating regulatory T cells, attenuating effector T cells, and reducing inflammation, using methods like tangential flow filtration to enrich vesicles with bioactive cargoes including microRNAs and mitochondria.

Benefits of technology

The extracellular vesicles effectively preserve and restore pancreatic islet beta-cell function, reduce inflammation, and enhance glucose-responsive insulin secretion, improving islet graft survival and reducing the need for immunosuppression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000032_0000
    Figure 00000032_0000
  • Figure 00000032_0001
    Figure 00000032_0001
  • Figure 00000032_0002
    Figure 00000032_0002
Patent Text Reader

Abstract

Disclosed herein are compositions comprising extracellular vesicles derived from mesenchymal stromal / stem cells, including human umbilical cord-derived mesenchymal stromal / stem cells, and methods of using such compositions for immunomodulation, mitochondrial transfer, preservation of cellular bioenergetics, and protection of pancreatic islet beta cells. The extracellular vesicles may comprise exosomes, small extracellular vesicles, medium or large extracellular vesicles, or an extracellular-vesicle-enriched fraction, including a tangential flow filtration retentate. The vesicles may contain immunomodulatory microRNAs and functional mitochondria capable of transfer to recipient cells. The compositions may stimulate regulatory T cells, attenuate effector T cells, induce T-cell exhaustion, polarize macrophages toward anti-inflammatory phenotypes, and preserve or restore glucose-responsive insulin or C-peptide secretion under inflammatory, immune-mediated, or mitochondrial stress. The compositions may be used to protect pancreatic islets, improve islet transplantation, reduce graft rejection, treat beta-cell dysfunction, and treat inflammatory, autoimmune, alloimmune, fibrotic, or immune-mediated disease.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] EXOSOMES AND SMALL EXTRACELLULAR VESICLES (sEVs) DERIVED FROM MESENCHYMAL STROMAL / STEM CELLS FOR IMMUNOMODULATION, MITOCHONDRIAL TRANSFER, AND THE PROTECTION OF PANCREATIC ISLET CELLS

[0002] RELATED APPLICATIONS

[0003] This application claims the benefit of U.S. Provisional Application No. 63 / 800,932, filed May 6, 2025, which is incorporated by reference herein in its entirety.

[0004] FIELD OF THE INVENTION

[0005] The present disclosure relates generally to biotechnology, regenerative medicine, extracellular vesicle therapeutics, cell-free therapies, transplantation, diabetes, and immunomodulation. More particularly, the disclosure relates to extracellular vesicles derived from mesenchymal stromal / stem cells, including human umbilical cord-derived mesenchymal stromal / stem cells, and to their use for immunomodulation, mitochondrial transfer, preservation or restoration of cellular bioenergetic function, and protection of pancreatic islet cells and other target cells, tissues, organoids, organs, grafts, or transplants from inflammatory, autoimmune, alloimmune, metabolic, oxidative, mitochondrial, fibrotic, or immune -mediated injury.

[0006] BACKGROUND

[0007] Type 1 Diabetes is characterized by immune-mediated destruction of insulin-producing pancreatic beta cells. Although insulin therapy is life-sustaining, it does not fully recapitulate physiological glucose regulation and does not eliminate the risk of hypoglycemia or long-term complications. Pancreatic islet transplantation and stem-cell-derived islet replacement strategies offer therapeutic potential, but their broader use is limited by inflammation, alloimmune rejection, recurrent autoimmunity, graft loss, and the need for chronic systemic immunosuppression .

[0008] Mesenchymal stromal / stem cells exhibit immunomodulatory and tissue-protective properties.

[0009] Extracellular vesicles released by such cells, including exosomes and other small, medium, or large extracellular vesicles, can carry bioactive cargo such as microRNAs, proteins, lipids, metabolites, and mitochondria or mitochondrial components. However, there remains a need for defined extracellular-vesicle compositions and manufacturing methods that provide coordinated immunomodulation, mitochondrial transfer, and protection of pancreatic islet cells and other target tissues under inflammatory, immune-mediated, and mitochondrial stress.

[0010] SUMMARY

[0011] The compositions and methods disclosed herein address the above-described needs by providing, in various embodiments, extracellular-vesicle compositions derived from mesenchymal stromal / stem cells, including Umbilical Cord-derived MSC (UC-MSCs), that are capable of modulating immune responses,stimulating regulatory T cells, attenuating effector T cells, inducing T-cell exhaustion, polarizing macrophages toward anti-inflammatory phenotypes, transferring functional mitochondria, preserving or restoring cellular bioenergetics, and protecting pancreatic islets and other target cells or tissues from injury.

[0012] In certain embodiments, the disclosure provides a composition comprising extracellular vesicles derived from mesenchymal stromal / stem cells (MSCs), wherein the extracellular vesicles comprise exosomes, small extracellular vesicles, medium extracellular vesicles, large extracellular vesicles, or an extracellular-vesicle-enriched fraction. In some embodiments, tire extracellular vesicles comprise one or more bioactive cargoes capable of preserving, restoring, or enhancing pancreatic islet beta-cell function under inflammatory stress, immune-mediated stress, mitochondrial stress, or combinations thereof. In other embodiments, the extracellular vesicles modulate an immune response, stimulate regulatory T cells, inhibit, reduce, attenuate, or reprogram effector T cells, reduce inflammation, reduce fibrosis, promote tissue repair, induce T-cell exhaustion, transfer functional mitochondria, preserve or restore cellular bioenergetic function, or protect target cells, tissues, organoids, organs, grafts, or transplants from injury.

[0013] In preferred embodiments, the extracellular vesicles are derived from human umbilical cord-derived MSCs (UC-MSCs). In some embodiments, the extracellular vesicles comprise an enriched cargo of immunomodulatory microRNAs. In some embodiments, the extracellular vesicles comprise functional mitochondria capable of being transferred to recipient pancreatic islet cells, immune cells, or other target cells.

[0014] In certain embodiments, the disclosure provides methods for generating extracellular-vesicle-enriched compositions from MSC-conditioned medium or UC-MSC-conditioned medium, including by tangential flow filtration (TFF), optionally with prior filtration. In some embodiments, a TFF retentate comprises a heterogeneous extracellular-vesicle-enriched fraction containing vesicles or vesicle-associated particles over a broad particle-size range.

[0015] In certain embodiments, the disclosure provides methods for preserving or restoring glucoseresponsive insulin secretion in pancreatic islet beta cells, methods for protecting pancreatic islets from immune-mediated attack, methods for inducing or stabilizing regulatory T cells, methods for inducing exhaustion or functional attenuation of effector T cells, methods for inducing anti-inflammatory macrophage polarization, methods for transferring functional mitochondria to pancreatic islet cells, methods for qualifying therapeutically active extracellular-vesicle preparations, and methods for treating and preventing beta-cell dysfunction, diabetes, inflammatory disease, autoimmune disease, alloimmune disease, fibrosis, graft rejection, and immune-mediated tissue injury.

[0016] In some embodiments, the invention provides a composition comprising extracellular vesicles derived from mesenchymal stromal / stem cells (MSCs), wherein the extracellular vesicles comprise exosomes, small extracellular vesicles, medium extracellular vesicles, large extracellular vesicles, or an extracellular-vesicle-enriched fraction, and wherein the extracellular vesicles comprise one or more bioactive cargoes capable of one or more of: preserving, restoring, or enhancing pancreatic islet beta-cell function under inflammatorystress, immune-mediated stress, mitochondrial stress, or a combination thereof; modulating an immune response; stimulating regulatory T cells; inhibiting, reducing, attenuating, or reprogramming effector T cells; reducing inflammation; reducing fibrosis; promoting tissue repair; inducing T-cell exhaustion; transferring functional mitochondria: preserving or restoring cellular bioenergetic function; and protecting a target cell, tissue, organoid, organ, graft, or transplant from inflammatory, autoimmune, alloimmune, metabolic, oxidative, mitochondrial, fibrotic, or immune-mediated injury.

[0017] In some embodiments, the MSCs comprise human umbilical cord-derived MSCs (UC-MSCs).

[0018] In some embodiments, the extracellular vesicles comprise an enriched cargo of immunomodulatory microRNAs.

[0019] In some embodiments, the immunomodulatory’ microRNAs comprise one or more of let-7a-5p, let-7c-5p, miR-486-5p, miR-432-5p, miR-125b-5p, miR-25-3p, miR-760, miR-425-5p, miR-320a-3p, miR-142-3p, miR-612, miR-107, miR-21-5p, let-7e-5p, miR-125a, miR-125a-3p, miR-146a-5p, miR-29b-3p, miR-103-3p, miR-125b-3p, miR-148a-3p, miR-27a-3p, miR-126a-3p, miR-223-3p, miR-92a-3p, miR-100-5p, miR-130a-3p, miR-16-5p, miR-320b, miR-382-5p, miR-423-5p, miR-494-3p, miR-721, or miR-193a-3p.

[0020] In some embodiments, the extracellular vesicles comprise functional mitochondria, respiring mitochondria, mitochondria-derived vesicles, mitochondrial components, mitochondrial proteins, mitochondrial DNA, mitochondrial RNA, or combinations thereof, capable of being transferred to one or more cells selected from pancreatic islet cells, beta cells, immune cells, T cells, regulatory’ T cells, effector T cells, macrophages, monocytes, endothelial cells, stromal cells, organoid cells, graft cells, donor cells, recipient cells, transplant cells, or injured cells.

[0021] In some embodiments, the functional mitochondria are respiring mitochondria detectable by a mitochondrial membrane-potential-dependent dye.

[0022] In some embodiments, the extracellular vesicles display one or more extracellular-vesicle-associated surface markers selected from CD9, CD63, and CD81.

[0023] In some embodiments, the extracellular vesicles have a diameter of about 5 nrn to about 200 nm, or about 5 nm to about 450 nm.

[0024] In some embodiments, the extracellular vesicles are present in a tangential flow filtration (TFF) retentate generated from UC-MSC conditioned medium, wherein the UC-MSC conditioned medium is optionally filtered prior to TFF, and wherein said optional filtration defines an approximate upper size range of particles retained in the TFF retentate.

[0025] In some embodiments, the retentate is enriched for particles retained by a tangential flow filtration membrane having a cutoff of about 5 nm.

[0026] In some embodiments, the MSCs are cultured under serum-free, xeno-free, and / or cGMP-compliant conditions.In some embodiments, the extracellular vesicles are formulated for storage at -80 degrees C or below while retaining biological activity.

[0027] In some embodiments, the extracellular vesicles are formulated for refrigerated storage, frozen storage, cryogenic storage, lyophilization, vitrification, spray drying, low-temperature drying, or reconstitution after drying .

[0028] In some embodiments, the invention provides a method for preserving or restoring glucose-responsive insulin secretion in pancreatic islet beta cells, comprising contacting pancreatic islets with an effective amount of the above-described composition.

[0029] In some embodiments, the pancreatic islets are inflamed, have been exposed to one or more inflammatory cytokines, exhibit increased expression of one or more HLA molecules, are subject to autoimmune or alloimmune recognition, are exposed to immune-mediated attack, and / or are obtained from, transplanted into, or present in a subject who is positive for one or more islet autoantibodies.

[0030] In some embodiments, the inflammatory cytokines comprise TNF -alpha, IFN-gamma, IL-1 beta, IL-6, IL- 17, or a combination thereof.

[0031] In some embodiments, the pancreatic islets have been exposed to, are exposed to, or are at increased risk of exposure to activated T cells, islet-reactive T cells, donor-reactive T cells, or a combination thereof.

[0032] In some embodiments, the T cells recognize, or are activated by, one or more islet beta-cell antigens, pancreatic cell antigens, anti-CD3 / CD28 stimulation, interleukin-2, or a combination thereof.

[0033] In some embodiments, the pancreatic islets are exposed to combined inflammatory cytokines and activated T cells.

[0034] In some embodiments, preserving or restoring glucose-responsive insulin secretion comprises increasing C-peptide release under high-glucose stimulation relative to untreated inflamed or immune -attacked islets.

[0035] In some embodiments, preserving or restoring glucose-responsive insulin secretion comprises improving a glucose-stimulated insulin release delta or a glucose-stimulated insulin release stimulation index.

[0036] hi some embodiments, the pancreatic islets are human pancreatic islets.

[0037] In some embodiments, the pancreatic islets are non-human pancreatic islets comprising non-human primate, canine, feline, equine, porcine, or bovine pancreatic islets.

[0038] In some embodiments, the pancreatic islets comprise cadaveric donor islets, stem-cell -derived islets, islet-like clusters, beta-cell organoids, insulin-producing cells, or beta-cell -containing cell preparations.

[0039] In some embodiments, the invention provides a method for protecting pancreatic islets from immune-mediated attack, comprising administering to or contacting the pancreatic islets with an effective amount of MSC-derived extracellular vesicles, wherein the extracellular vesicles reduce beta-cell dysfunction caused by inflammation and / or activated T cells.In some embodiments, the immune-mediated attack comprises alloimmune rejection, autoimmune attack, inflammatory injury, cytotoxic T-cell attack, or a combination thereof.

[0040] In some embodiments, the extracellular vesicles reduce CD8+ CD45RA+ CCR7- effector T cells, reduce CD4+ CD45RA+ CCR7- effector T cells, increase PD-1+ exhausted CD8+ T cells, increase TIM-3+ exhausted T cells, or any combination thereof.

[0041] In some embodiments, the extracellular vesicles reduce CD4+ PD-1- CD57+ T cells associated with transplant rejection.

[0042] In some embodiments, the invention provides a method for treating, preventing, or reducing progression of beta-cell dysfunction in a subject, comprising administering to the subject an effective amount of the above-described composition.

[0043] In some embodiments, the subject has, is at risk of developing, or is undergoing treatment for Type 1 Diabetes, Type 2 Diabetes, latent autoimmune diabetes in adults, recurrent autoimmunity after islet transplantation, or beta-cell dysfunction associated with inflammation.

[0044] In some embodiments, the composition is administered before, during, or after pancreatic islet transplantation.

[0045] In some embodiments, administration reduces the need for exogenous insulin administration or systemic immunosuppression, improves islet graft survival, improves islet graft function, delays graft rejection, promotes graft tolerance, or any combination thereof.

[0046] In some embodiments, the composition is administered intravenously, intra-arterially, intraportally, intrapancreatically, intraabdominally, locally to a transplant site, onto the omentum, into an omental pouch, into a subcutaneous implant site, or ex vivo to an islet preparation prior to transplantation.

[0047] In some embodiments, the invention provides a method for inducing, expanding, activating, or stabilizing regulatory T cells (Tregs), comprising contacting T cells with the above-described composition, wherein the contacting increases CD4+ CD25+ FOXP3+ regulatory T cells, Helios+ regulatory T cells, proliferating FOXP3+ MKI67+ regulatory T cells, or a regulatory T-cell subset co-expressing one or more of TGFB1, IL 10, IKZF2, CTLA4, ENTPD1, orNT5E.

[0048] In some embodiments, the regulatory T cells comprise T cells obtained from a healthy donor or from a subject with Type 1 Diabetes.

[0049] In some embodiments, the invention provides a method for inducing exhaustion or functional attenuation of effector T cells, comprising contacting T cells with the above-described composition, wherein the contacting increases expression of PDCD1 / PD-1, HAVCR2 / TIM-3, or both, and / or decreases expression of TNF, IFNG, EOMES, or any combination thereof.

[0050] In some embodiments, the invention provides a method for inducing an anti-inflammatory macrophage phenotype, comprising contacting macrophages with the above-described composition, whereinexpression of one or more of CD163, IL-10, IL-1R2, or MRC1 is increased, and / or expression of one or more of TNF, IFN-gamma, or IL-6 is decreased.

[0051] In some embodiments, the invention provides a method for transferring functional mitochondria to pancreatic islet cells, comprising contacting pancreatic islets with the above-described composition, wherein functional mitochondria from MSC-derived or UC-MSC-derived extracellular vesicles or tangential flow fdtration retentate are transferred to the pancreatic islet cells.

[0052] In some embodiments, the pancreatic islet cells have mitochondrial dysfunction or are at risk of mitochondrial dysfunction induced by ischemia, oxidative stress, inflammatory stress, immune-mediated injury, antimycin A, or any combination thereof.

[0053] In some embodiments, the transfer of functional mitochondria restores mitochondrial respiratory activity, preserves islet morphology, increases islet survival, or restores glucose-responsive C-peptide secretion.

[0054] In some embodiments, the invention provides a method for identifying or qualifying a therapeutically active MSC extracellular-vesicle preparation, comprising assaying the preparation for one or more potency attributes selected from: expansion of CD4+ CD25+ FOXP3+ regulatory T cells (Tregs); increase of Helios+ regulatory T cells (activated Tregs); decrease of CD45RA+ resting regulatory T cells (resting Tregs); reduction of CD8+ CD45RA+ CCR7- effector T cells; increase of CD8+ PD-1+ exhausted T cells; induction of an antiinflammatory macrophage phenotype; preservation of glucose-responsive C-peptide secretion in inflamed islets; preservation of glucose-responsive C-peptide secretion in an islet immune attack model; mitochondrial transfer to islet cells; mitochondrial respiratory activity; and presence of an immunomodulatory miRNA signature.

[0055] In some embodiments, the immunomodulatory signature of the extracellular-vesicle preparation comprises functional mitochondria and / or one or more miRNAs predicted to regulate IL-10, TGF-betal , SMAD2, SMAD3, MRC1, CD 163, VEGFA, insulin, or pathways associated with immune tolerance, stress adaptation, angiogenesis, or beta-cell survival.

[0056] hi some embodiments, the method further comprises excluding or deprioritizing an extracellular-vesicle preparation in which mitochondrial impairment of the extracellular vesicles reduces or abolishes Treg expansion, Treg activation, beta-cell protection, mitochondrial transfer, or restoration of glucose-responsive insulin secretion.

[0057] In some embodiments, the invention provides a method for manufacturing a UC-MSC extracellular-vcsiclc composition, comprising culturing human UC-MSCs under scrum-free, xcno-frcc, and / or cGMP-compliant conditions; collecting conditioned medium; optionally removing cells and debris; optionally filtering the conditioned medium; and concentrating an extracellular-vesicle-enriched retentate by tangential flow filtration.In some embodiments, the conditioned medium is generated after about 12, 24, 48, 72, or 96 hours of UC-MSC culture.

[0058] In some embodiments, the removing of cells and debris comprises centrifugation and the filtering comprises filtration through a membrane of about 0.2 micrometers or about 0.45 micrometers.

[0059] In some embodiments, the tangential flow filtration generates a retentate enriched for particles having a diameter of about 5 nm to about 450 nm, about 5 nm to about 300 nm, about 5 nm to about 200 nm, about 30 nm to about 200 nm, about 50 nm to about 250 nm, about 100 nm to about 300 nm, or about 100 nm to about 450 nm.

[0060] In some embodiments, the method further comprises characterizing the extracellular-vesicle-enriched retentate by nanoparticle tracking analysis, dynamic light scattering, nano-flow cytometry, extracellular-vesicle surface marker profiling, miRNA profiling, mitochondrial-function analysis, or any combination thereof.

[0061] In some embodiments, the method further comprises testing the extracellular-vesicle-enriched retentate in a human Treg expansion assay, a macrophage polarization assay, a human islet inflammation model, a human islet immune attack model, a mitochondrial transfer assay, or any combination thereof.

[0062] In some embodiments, the invention provides an extracellular-vesicle-enriched retentate produced by a method for manufacturing a UC-MSC extracellular-vesicle composition, comprising culturing human UC-MSCs under serum-free, xeno-free, and / or cGMP-compliant conditions; collecting conditioned medium; optionally removing cells and debris; optionally filtering tire conditioned medium; and concentrating an extracellular-vesicle-enriched retentate by tangential flow filtration.

[0063] In some embodiments, the invention provides pharmaceutical composition comprising composition comprising extracellular vesicles derived from mesenchymal stromal / stem cells (MSCs), wherein the extracellular vesicles comprise exosomes, small extracellular vesicles, medium extracellular vesicles, large extracellular vesicles, or an extracellular-vesicle-enriched fraction, and wherein the extracellular vesicles comprise one or more bioactive cargoes capable of one or more of: preserving, restoring, or enhancing pancreatic islet beta-cell function under inflammatory stress, immune -mediated stress, mitochondrial stress, or a combination thereof; modulating an immune response: stimulating regulatory T cells; inhibiting, reducing, attenuating, or reprogramming effector T cells; reducing inflammation; reducing fibrosis; promoting tissue repair; inducing T-cell exhaustion; transferring functional mitochondria; preserving or restoring cellular bioenergetic function; and protecting a target cell, tissue, organoid, organ, graft, or transplant from inflammatory, autoimmune, alloimmunc, metabolic, oxidative, mitochondrial, fibrotic, or immunc-mcdiatcd injury; and a pharmaceutically acceptable carrier, buffer, excipient, stabilizer, cryoprotectant, or diluent.

[0064] In some embodiments, the invention provides a use of said composition for the manufacture of a medicament for preserving, restoring, or enhancing pancreatic beta-cell function; protecting pancreatic islets; preserving glucose-responsive insulin secretion; restoring C-peptide secretion; reducing inflammatory,autoimmune, alloimmune, or immune-mediated beta-cell injury: improving the survival, engraftment, function, or durability of transplanted pancreatic islets or insulin-producing cells; inducing, promoting, or maintaining immune tolerance; reducing or preventing alloimmune rejection; reducing or preventing autoimmune beta-cell destruction; treating, preventing, delaying the onset of, slowing the progression of, or ameliorating Type 1 Diabetes; treating Type 2 Diabetes associated with islet inflammation or beta-cell dysfunction; treating beta-cell dysfunction associated with inflammatory, metabolic, oxidative, mitochondrial, or immune-mediated injury'; modulating inflammation; treating inflammatory' disease; treating fibrosis or fibrotic disease; correcting immune imbalance; suppressing effector T cells; reducing cytotoxic T-cell activity; inducing T-cell exhaustion; expanding, activating, or stabilizing regulatory T cells; polarizing macrophages toward an anti-inflammatory M2 or M2-like phenotype; reducing pro-inflammatory cytokine production; promoting tissue repair; improving transplantation outcomes: reducing the need for systemic immunosuppression; and / or preventing, reducing, or treating graft rejection.

[0065] In some embodiments, tire extracellular vesicles are hypoimmune extracellular vesicles engineered to reduce recognition by host immune cells.

[0066] In some embodiments, the hypoimmune extracellular vesicles have reduced or absent presentation of one or more human leukocyte antigen (HLA) molecules.

[0067] In some embodiments, the one or more HLA molecules comprise one or more of HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, HLA-DP, beta-2 microglobulin, or CIITA-regulated HLA class II molecules.

[0068] In some embodiments, the hypoimmune extracellular vesicles are derived from UC-MSCs genetically modified to reduce expression, loading, or surface presentation of one or more HLA class I or HLA class II molecules on the extracellular vesicles.

[0069] In some embodiments, the hypoimmune extracellular vesicles are engineered to express or display one or more immune-evasive molecules.

[0070] In some embodiments, the one or more immune-evasive molecules comprise one or more of CD47, PD-L1, HLA-E, HLA-G, CD24, CD55, CD59, or a functional fragment or variant thereof.

[0071] hi some embodiments, the hypoimmune extracellular vesicles are engineered to reduce uptake, clearance, complement activation, antibody binding, NK-cell activation, macrophage-mediated phagocytosis, T-cell activation, or alloimmune recognition.

[0072] In some embodiments, the hypoimmune extracellular vesicles are produced from UC-MSCs modified by one or more of CRISPR / Cas-mediated genome editing, RNA interference, shRNA, siRNA, antisense oligonucleotides, epigenetic modulation, transgcnc expression, mRNA transfection, viral transduction, non-viral transfection, or cell-culture priming.

[0073] In some embodiments, the hypoimmune extracellular vesicles retain one or more functional properties selected from Treg expansion, Treg activation, reduction of effector T cells, induction of T-cell exhaustion,M2 -like macrophage polarization, mitochondrial transfer, preservation of beta-cell viability, and preservation or restoration of glucose-stimulated insulin release or glucose-stimulated C-peptide release.

[0074] In some embodiments, the invention provides a pharmacal composition comprising composition comprising extracellular vesicles derived from mesenchymal stromal / stem cells (MSCs), wherein the extracellular vesicles comprise exosomes, small extracellular vesicles, medium extracellular vesicles, large extracellular vesicles, or an extracellular-vesicle-enriched fraction, and wherein the extracellular vesicles comprise one or more bioactive cargoes capable of one or more of: preserving, restoring, or enhancing pancreatic islet beta-cell function under inflammatory stress, immune -mediated stress, mitochondrial stress, or a combination thereof; modulating an immune response; stimulating regulatory T cells; inhibiting, reducing, attenuating, or reprogramming effector T cells; reducing inflammation; reducing fibrosis; promoting tissue repair; inducing T-cell exhaustion; transferring functional mitochondria; preserving or restoring cellular bioenergetic function; and protecting a target cell, tissue, organoid, organ, graft, or transplant from inflammatory, autoimmune, alloimmune, metabolic, oxidative, mitochondrial, fibrotic, or immune-mediated injury, wherein the extracellular vesicles are hypoimmune extracellular vesicles engineered to reduce recognition by host immune cells; and a pharmaceutically acceptable carrier, buffer, excipient, stabilizer, cryoprotectant, or diluent.

[0075] In some embodiments, the invention provides a use of said composition for the manufacture of a medicament for preserving, restoring, or enhancing pancreatic beta-cell function; protecting pancreatic islets; preserving glucose-responsive insulin secretion; restoring C-peptide secretion; reducing inflammatory, autoimmune, alloimmune, or immune-mediated beta-cell injury; improving the survival, engraftment, function, or durability of transplanted pancreatic islets or insulin-producing cells; inducing, promoting, or maintaining immune tolerance; reducing or preventing alloimmune rejection; reducing or preventing autoimmune beta-cell destruction; treating, preventing, delaying the onset of, slowing the progression of, or ameliorating Type 1 Diabetes; treating Type 2 Diabetes associated with islet inflammation or beta-cell dysfunction; treating beta-cell dysfunction associated with inflammatory, metabolic, oxidative, mitochondrial, or immune-mediated injury; modulating inflammation; treating inflammatory disease; treating fibrosis or fibrotic disease; correcting immune imbalance; suppressing effector T cells; reducing cytotoxic T-cell activity; inducing T-cell exhaustion; expanding, activating, or stabilizing regulatory T cells; polarizing macrophages toward an anti-inflammatory M2 or M2-like phenotype; reducing pro-inflammatory cytokine production: promoting tissue repair; improving transplantation outcomes; reducing the need for systemic immunosuppression; and / or preventing, reducing, or treating graft rejection.

[0076] Additional features and advantages of embodiments of the present invention are described further below. This summary section is meant merely to illustrate certain features of embodiments of the invention, and is not meant to limit the scope of the invention in any way. The failure to discuss a specific feature orembodiment of the invention, or the inclusion of one or more features in this summary section, should not be construed to limit the invention as claimed.

[0077] BRIEF DESCRIPTION OF THE DRAWINGS

[0078] The foregoing summary, as well as the following detailed description of certain embodiments of the application, will be better understood when read in conjunction with the appended drawings. For the purposes of illustrating the compositions and methods of the present application, there are shown in the drawings preferred embodiments. It should be understood, however, that the application is not limited to the precise embodiments shown.

[0079] FIG. 1 shows characterization of UC-MSC-derived extracellular vesicles and their immunomodulatory effects. Panel A shows that in cultures of activated T cells, UC-MSC conditioned medium stimulates an expansion of human CD4+CD25+FOXP3+ regulatory T cells (T regs), as analyzed via flow cytometry. Panel B schematically depicts processing of UC-MSC conditioned medium by tangential flow filtration to generate an EV-enriched retentate fraction containing particles with diameters of approximately 5-200 nm and a permeate fraction containing cytokines and growth factors below- approximately 5 nm. Panels C-E show EV physical characterization by dynamic light scattering, nano-flow cytometry, and nanoparticle tracking analysis, confirming the purification of nanoscale particles within the EV size range. Panels F-H show that the EV fraction promotes human Treg expansion and Helios+ Treg activation, and reduces resting CD45RA+ Tregs, whereas the cytokine-and-growth-factor fraction does not reproduce this activity. Panels I-L show dosedependent Treg expansion and activation, inhibition of CD8+ effector T cells, and induction of CD8+PD-1+ exhausted T cells. Panel M shows that UC-MSC EVs polarize macrophages derived from the THP-1 monocytic cell line toward an anti-inflammatory M2 / M2-like phenotype, including increased gene expression of CD 163, IL- 10, and IL-1R2 and decreased expression of IL-6, TNF, and IFN -gamma.

[0080] FIG. 2 show s that UC-MSC EVs preserve and / or restore beta-cell function in a human pancreatic islet inflammation model. Panels A-B schematically depict exposure of primary human islets to TNF-alpha and IFN-gamma followed by UC-MSC EV treatment and glucose-stimulated insulin release testing. Panels C-D show that, in an assay of glucose-stimulated insulin (C-peptide) release, human islets exposed to inflammatory cytokines exhibit a reduced C-peptide secretion from beta cells across low glucose, high glucose, second low glucose, and KC1 stimulation steps, whereas UC-MSC EV treatment preserves or restores C-peptide release. Panels E-F show- that EV treatment improves glucose-stimulated insulin (C-peptide) release (GSIR) delta and stimulation index in inflamed islets.

[0081] FIG. 3 shows that UC-MSC EVs protect beta-cell function in a human islet immune attack model. Panels A-B schematically depict a model in which human islets are initially rendered inflamed via exposure to TNF-alpha and IFN-gamma, subsequently co-cultured with activated human T cells (activated via anti-CD3 / CD28 and IL-2), and treated with or without UC-MSC EVs, followed by GSIR testing. Panels C-D show-that combined inflammation and T-cell-mediated attack markedly impair C-peptide secretion, whereas UC-MSC EV treatment substantially preserves glucose-responsive insulin (C-peptide) release. Panels E-F show that UC-MSC EV treatment improves GSIR delta and stimulation index under immune attack conditions.

[0082] FIG. 4 shows immune-cell phenotypes emerging in culture in the human islet immune attack model. Panel A depicts recovery7and flow-cytometric analysis of T cells after co-culture. Panels B-C show that EV treatment reduces high-scatter and low-scatter CD8+CD45RA+CCR7- effector T cells. Panel D shows that EV treatment leads to increased CD8+PD-1+ exhausted T cells. Panels E-F show that EV treatment leads to reductions in CD4+CD45RA+CCR7- effector T cells. Panels G-H show that EV treatment leads to suppression of CD4+PD-1-CD57+ T cells, a population of cells associated with transplant rejection.

[0083] FIG. 5 shows single-cell RNA sequencing analysis demonstrating that UC-MSC EVs reprogram human immune cells toward regulatory and exhausted states and away from inflammatory / cytotoxic states. Panels A-C depict the scRNA-seq workflow and UMAP embeddings for healthy and Type 1 Diabetes donor cells under control and EV-treated conditions. Panel D shows marker-defined immune transcriptional programs. Panels E-F show increased regulatory T-cell phenotypes, including CD4+IL2RA+FOXP3+ Tregs co-expressing TGFB1. IL10. IKZF2. CTLA4, ENTPD1. NT5E, and MKI67. Panels G and I show increased exhaustion markers including PDCD1 / PD-1 and HAVCR2 / T1M-3 in CD4+ and CD8+ T cells. Panels H and J show decreased pro-inflammatory / cytotoxic markers including TNF, IFNG, and EOMES in CD4+ and CD8+ T cells. These observations are in line with the ones made via flow cytometry.

[0084] FIG. 6 shows that UC-MSC EVs transfer functional mitochondria to human pancreatic islets and that intact mitochondrial fiinction within EVs is required for full immunomodulatory activity. Panels A-B show that MitoTracker-labeled, respiring EV mitochondria are transferred to islets, whereas antimycin A-impaired EV mitochondria do not generate the same functional mitochondrial signal. Panels C-F show that EV treatment rescues islet morphology, mitochondrial respiratory signal, and glucose-responsive C-peptide secretion after antimycin A-induced mitochondrial impairment. Panels G-J show that antimycin A-mediated impairment of EV mitochondrial fiinction abolishes or substantially reduces EV-induced Treg expansion, Helios+ Treg activation, and reduction of resting Tregs.

[0085] Figure 7 shows microRNA (miRNA) cargo analysis of UC-MSC EVs. Panels A-C depict miRNA isolation, sequencing, and qPCR profiling, including consistently enriched miRNAs and a larger set of highly present miRNAs. Panel D shows predicted targeting of genes involved in immune regulation and tissue repair, including IL-10, TGF-betal, MRC1, CD163, and VEGFA. Panel E shows enriched functional categories for predicted miRNA targets, including immune system pathways, stress responses, growth-factor signaling, vesicle-mediated transport, and toll-like receptor cascades. Panel F shows pathway-network analysis linking EV miRNAs to beta-cell fiinction and immune regulation targets, including insulin, TGF-beta. SMAD2 / 3. and G-protein complex nodes. Panels G-I show increased expression of SMAD2, SMAD3, and TGF-betal inFOXP3+IL2RA+CD4+ Tregs after EV treatment, supporting miRNA-associated transcriptional reprogramming.

[0086] DETAILED DESCRIPTION

[0087] Definitions

[0088] As used herein, the terms "extracellular vesicle" and "EV" broadly refer to lipid membrane-bound vesicles or vesicle-enriched particles released by cells, including exosomes, small extracellular vesicles, medium extracellular vesicles, large extracellular vesicles, microvesicles, organelle-containing vesicles, mitochondria-containing vesicles, vesicle aggregates, protein-vesicle complexes, and extracellular-vesicle-enriched fractions. Unless otherwise specified, reference to extracellular vesicles includes natural, enriched, isolated, concentrated, formulated, engineered, modified, hypoimmune, or immune-evasive extracellular vesicles.

[0089] As used herein, the term "about" includes variations generally accepted in the art for tire relevant measurement, including measurement variability, biological variability, instrument variability, manufacturing variability, and rounding. In some embodiments, "about" means within 10%, within 20%, or within an accepted technical tolerance of the stated value.

[0090] As used herein, "bioactive cargo" includes nucleic acids, microRNAs, messenger RNAs, long noncoding RNAs, circular RNAs, proteins, enzymes, cytokines, growth factors, lipids, metabolites, mitochondrial proteins, mitochondrial DNA, mitochondria-derived vesicles, intact mitochondria, functional mitochondria, and combinations thereof.

[0091] As used herein, "pancreatic islets" includes human and non-human islets, cadaveric donor islets, allogeneic islets, autologous islets, xenogeneic islets, stem-cell-derived islets, islet-like clusters, beta-cell organoids, insulin-producing cells, beta-cell -containing cell preparations, and genetically modified insulinproducing cells.

[0092] Overview

[0093] The present disclosure relates to compositions comprising extracellular vesicles derived from mesenchymal stromal / stem cells (MSCs), including but not limited to human umbilical cord-derived mesenchymal stromal / stem cells (UC-MSCs), and to methods of using such compositions for immunomodulation, mitochondrial transfer, preservation or restoration of cellular bioenergetics, protection of pancreatic islet cells, protection of transplanted cells or tissues, and treatment or prevention of inflammatory, autoimmune, alloimmune, metabolic, mitochondrial, fibrotic, or immune-mediated injury.

[0094] In certain embodiments, the extracellular vesicles comprise exosomes. small extracellular vesicles, medium extracellular vesicles, large extracellular vesicles, microvesicles, organelle-containing vesicles, mitochondria-containing vesicles, vesicle aggregates, protein-vesicle complexes, or an extracellular-vesicle-enriched fraction. In preferred embodiments, the extracellular vesicles are derived from UC-MSC conditioned medium and are enriched by tangential flow filtration (TFF). In particular embodiments, the extracellular vesicle-enriched fraction comprises a TFF retentate containing bioactive vesicular and vesicle-associated components capable of modulating immune-cell phenotype or function, stimulating regulatory T cells, reducing or reprogramming effector T cells, inducing T-cell exhaustion, polarizing macrophages toward antiinflammatory phenotypes, transferring functional mitochondria, preserving or restoring mitochondrial function, and protecting pancreatic islet beta cells or other target cells from inflammatory, immune -mediated, oxidative, metabolic, fibrotic, or mitochondrial stress.

[0095] The compositions disclosed herein may be used to preserve, restore, or enhance pancreatic islet betacell function, glucose-responsive insulin secretion, and C-peptide secretion under inflammatory stress, immune-mediated stress, mitochondrial stress, or combinations thereof. The compositions may also be used to improve the survival, function, engraftment, or durability of pancreatic islets, stem-cell-derived islets, islet-like clusters, beta-cell organoids, insulin-producing cells, transplanted cells, tissues, organoids, organs, grafts, or transplants.

[0096] Extracellular Vesicle Source

[0097] In some embodiments, the extracellular vesicles are derived from MSCs obtained from one or more tissues selected from umbilical cord, Wharton's jelly, placenta, amniotic membrane, amniotic fluid, bone marrow, adipose tissue, dental pulp, menstrual blood, peripheral blood, induced pluripotent stem cell-derived MSCs, embryonic stem cell-derived MSCs, or other stromal or mesenchymal progenitor-cell sources.

[0098] In preferred embodiments, the extracellular vesicles are derived from human UC-MSCs. UC-MSCs may be isolated, expanded, cryopreserved, banked, thawed, and cultured under serum-free, xeno-free. chemically defined, closed-system, and / or current Good Manufacturing Practice (cGMP)-compliant conditions. In some embodiments, UC-MSCs are cultured in monolayer culture, multilayer flasks, CellSTACK culture chambers, cluster culture, organoid culture, suspension culture systems, stirred-tank bioreactors, vertical wheel bioreactors, hollow-fiber bioreactors, microcarrier-based systems, or other scalable manufacturing systems.

[0099] In certain embodiments, UC-MSCs at a culture passage between passage 0 and passage 100 are cultured for about 6 hours to about 168 hours, including about 12, 24, 48, 72, 96, 120, or 144 hours, to generate conditioned medium. In preferred embodiments, UC-MSCs at passage 4, passage 5, or passage 6 are cultured for about 24 hours, about 48 hours, or about 72 hours to generate conditioned medium enriched for secreted extracellular vesicles and bioactive secretome components.Conditioned Medium Processing and TFF Retentate

[0100] Conditioned medium may be collected from MSC or UC-MSC cultures and processed to generate an extracellular-vesicle-enriched preparation. In some embodiments, conditioned medium is centrifuged, clarified, filtered, concentrated, diafiltered, washed, lyophilized, cryopreserved, or otherwise processed.

[0101] In certain embodiments, conditioned medium is processed by tangential flow filtration (TFF) with or without a prior filtration step. In some embodiments, the conditioned medium is filtered before TFF through a membrane having a pore size of about 0.1 micrometers, about 0.2 micrometers, about 0.22 micrometers, about 0.45 micrometers, about 0.65 micrometers, about 0.8 micrometers, about 1.0 micrometers, or another selected pore size. In such embodiments, the filtration step may establish an approximate upper particle-size limit for particles present in the TFF retentate.

[0102] In other embodiments, conditioned medium is not filtered before TFF, thereby allowing larger vesicles, vesicle aggregates, protein-vesicle complexes, organelle-containing vesicles, mitochondria-containing vesicles, mitochondria, or other bioactive particles to be retained in the TFF retentate.

[0103] In some embodiments, the conditioned medium is processed using a TFF membrane having a pore size or molecular-weight cutoff selected to retain extracellular vesicles or vesicle-associated complexes. In certain embodiments, the TFF membrane has a cutoff of about 1 nm, about 3 nm, about 5 nm, about 10 nm, about 20 nm, about 30 nm, about 50 nm, about 100 kDa, about 300 kDa, about 500 kDa, about 750 kDa, or another suitable cutoff. In preferred embodiments, a TFF membrane having a cutoff of about 5 nm is used to generate a retentate enriched for extracellular vesicles and vesicle-associated particles.

[0104] The TFF process may generate a retentate enriched for extracellular vesicles and a permeate comprising soluble cytokines, growth factors, proteins, peptides, metabolites, or other components below the membrane cutoff. In certain embodiments, the retentate is enriched for particles having diameters of about 5 nm to about 450 nm. In some embodiments, the retentate is enriched for particles having a diameter of about 5 nm to about 300 nm, about 5 nm to about 200 nm, about 20 nm to about 450 nm, about 30 nm to about 200 nm, about 50 nm to about 250 nm, about 100 nm to about 300 nm, about 100 nm to about 450 nm, about 150 nm to about 450 nm, about 5 nm to about 450 nm, or about 200 nm to about 450 nm.

[0105] Particle Size and Physical Characterization

[0106] In certain embodiments, the extracellular-vesicle-enriched composition comprises particles having a diameter from about 5 nm to about 450 nm, including without limitation about 5 nm to about 20 nm, about 20 nm to about 50 nm, about 30 nm to about 200 nm, about 50 nm to about 200 nm, about 50 nm to about 250 nm, about 100 nm to about 300 nm, about 100 nm to about 450 nm, about 150 nm to about 450 nm, about 200 nm to about 450 nm. about 5 nm to about 200 nm, or about 5 nm to about 450 nm.

[0107] In particular embodiments, the composition comprises a heterogeneous extracellular-vesicle-enriched fraction having a multimodal particle-size distribution. In some embodiments, the composition comprises oneor more particle subpopulations with diameters approximately 8 nm, approximately 33 nm, approximately 175 nm, and / or larger vesicular or vesicle-associated particles up to about 450 nm.

[0108] The extracellular vesicles or EV-enriched fraction may be characterized by one or more methods including nanoparticle tracking analysis (NTA), dynamic light scattering (DLS). nano-flow cytometry, tunable resistive pulse sensing, electron microscopy, cryo-electron microscopy, atomic force microscopy, fluorescence microscopy, protein quantification, lipid quantification, RNA quantification, mitochondrial-function assays, and surface-marker profiling.

[0109] In certain embodiments, the extracellular vesicles display one or more extracellular-vesicle-associated surface markers selected from CD9, CD63, CD81, CD29, CD44, CD73, CD90, CD105, CD146, integrins. tetraspanins. or other vesicle-associated proteins. In preferred embodiments, the extracellular vesicles display one or more of CD9, CD63, and CD81.

[0110] Bioactive Cargo

[0111] The extracellular vesicles disclosed herein may comprise one or more bioactive cargoes, including microRNAs, messenger RNAs, long non-coding RNAs, circular RNAs, proteins, enzymes, cytokines, growth factors, lipids, metabolites, mitochondrial proteins, mitochondrial DNA, mitochondria-derived vesicles, intact mitochondria, functional mitochondria, or combinations thereof.

[0112] In certain embodiments, the bioactive cargo is capable of modulating immune responses, stimulating regulatory T cells, inhibiting effector T cells, inducing T-cell exhaustion, promoting anti-inflammatory macrophage polarization, reducing pro-inflammatory cytokines, reducing fibrosis, promoting tissue repair, transferring functional mitochondria, restoring cellular bioenergetics, or protecting target cells from injury.

[0113] In some embodiments, the bioactive cargo comprises an enriched cargo of immunomodulatory microRNAs. In particular embodiments, the microRNAs comprise one or more of let-7a-5p, let-7c-5p, miR-486-5p, miR-432-5p, miR-125b-5p, miR-25-3p, miR-760, miR-425-5p, miR-320a-3p, miR-142-3p, miR-612, miR-107, miR-21-5p, let-7e-5p, miR-125a, miR-125a-3p, miR-146a-5p, miR-29b-3p, miR-103-3p, miR-125b-3p. miR-148a-3p, miR-27a-3p, miR-126a-3p, miR-223-3p, miR-92a-3p, miR-100-5p, miR-130a-3p, miR-16-5p. miR-320b, miR-382-5p, miR-423-5p, miR-494-3p, miR-721, or miR-193a-3p.

[0114] In some embodiments, the microR A cargo comprises one or more miR As predicted to regulate 1L-10, TGF-betal, SMAD2, SMAD3, MRC1, CD163, VEGFA, insulin, or pathways associated with immune tolerance, stress adaptation, angiogenesis, beta-cell survival, mitochondrial function, anti-inflammatory effect, or tissue repair.

[0115] Functional Mitochondria and Mitochondrial Transfer

[0116] In certain embodiments, the extracellular vesicles comprise functional mitochondria, respiring mitochondria, mitochondria-derived vesicles, mitochondrial proteins, mitochondrial DNA, mitochondrialRNA, mitochondrial components, or components supporting mitochondrial biogenesis. In preferred embodiments, the extracellular vesicles comprise functional mitochondria capable of being transferred to recipient cells, including pancreatic islet cells, beta cells, immune cells, macrophages, T cells, organoids, graft cells, transplant cells, or other target cells.

[0117] Functional mitochondria may be identified or quantified by one or more assays measuring mitochondrial membrane potential, mitochondrial respiration, oxygen consumption rate, ATP production, mitochondrial dye uptake, MitoTracker staining, mitochondrial DNA content, mitochondrial protein content, or transfer of mitochondria-associated fluorescence to recipient cells. In some embodiments, functional mitochondria are respiring mitochondria detectable by a mitochondrial membrane-potential-dependent dye.

[0118] In some embodiments, extracellular vesicles transfer functional mitochondria to pancreatic islet cells and thereby restore mitochondrial respiratory activity, preserve islet morphology, increase islet survival, restore glucose-responsive C-peptide secretion, or preserve glucose-responsive insulin secretion. In certain embodiments, recipient cells have mitochondrial dysfunction induced by ischemia, hypoxia, oxidative stress, inflammatory stress, immune-mediated injury, cytokine exposure, antimycin A, rotenone, oligomycin, one or more drugs, one or more agents affecting mitochondrial function, metabolic stress, transplantation-related stress, or combinations thereof.

[0119] In certain embodiments, mitochondrial integrity within extracellular vesicles is a potency attribute. In some embodiments, impairment of extracellular-vesicle mitochondrial function, including by antimycin A or another mitochondrial inhibitor, reduces or abolishes one or more therapeutic functions of the extracellular vesicles, including Treg expansion, Treg activation, beta-cell protection, mitochondrial transfer, preservation of islet morphology, restoration of mitochondrial respiratory activity, or restoration of glucose-responsive insulin secretion.

[0120] Immunomodulatory Activity

[0121] The extracellular vesicle compositions disclosed herein may modulate one or more immune-cell populations. In certain embodiments, the compositions stimulate, induce, expand, activate, or stabilize regulatory T cells. Regulatory T cells may include CD4+CD25+FOXP3+ Tregs. Helios+ activated Tregs, FOXP3+MKI67+ proliferating Tregs, or Tregs co-expressing one or more of TGFB1, IL 10, IKZF2, CTLA4, ENTPD1, NT5E, TNFR2, CD39, or CD73.

[0122] In certain embodiments, the compositions reduce, inhibit, attenuate, or reprogram effector T cells. Effector T cells may include CD8+CD45RA+CCR7- T cells, CD4+CD45RA+CCR7- T cells, cytotoxic T cells, islet-reactive T cells, donor-reactive T cells, autoreactive T cells, alloreactive T cells, memory effector T cells, or transplant-rejection-associated T-cell subsets.

[0123] In some embodiments, the compositions induce exhausted or functionally attenuated T-cell phenotypes. Such phenotypes may include increased expression of PDCD1 / PD-1, HAVCR2 / TIM-3, CTLA4,LAG3, TIGIT, or other immune-checkpoint or exhaustion-associated markers. In some embodiments, the compositions reduce expression of pro-inflammatory or cytotoxic markers including TNF, IFNG, EOMES, GZMB, PRF1, NKG7, CCL3, CCL4, CCL5. or combinations thereof.

[0124] In some embodiments, the compositions reduce CD4+PD-1-CD57+ T cells associated with transplant rejection. In other embodiments, the compositions reduce cytotoxic or inflammatory immune states identified by flow cytometry, single-cell RNA sequencing, transcriptomic profiling, proteomic profiling, or other immune phenotyping methods.

[0125] Macrophage Polarization

[0126] In certain embodiments, the extracellular vesicle compositions induce an anti-inflammatory macrophage phenotype. The macrophages may comprise primary macrophages, monocytc-dcnvcd macrophages, THP-1 -derived macrophages, tissue-resident macrophages, graft-infiltrating macrophages, islet-associated macrophages, or macrophage-like cells.

[0127] In some embodiments, contacting macrophages with the extracellular vesicle composition increases expression of one or more anti-inflammatory or M2 / M2-like markers including CD163, IL-10, IL-1R2, MRC1, ARG1, CD206, TGF-beta, or combinations thereof. In some embodiments, contacting macrophages with the extracellular vesicle composition decreases expression of one or more pro-inflammatory markers including TNF, IFN-gamma, IL-6, IL-1 alpha, CXCL10, NOS2, or combinations thereof.

[0128] In certain embodiments, macrophage polarization contributes to reduced inflammation, reduced tissue injury, reduced graft rejection, improved tissue repair, angiogenesis, or improved survival and fiinction of transplanted cells or tissues.

[0129] Protection of Pancreatic Islets and Beta Cells

[0130] The compositions disclosed herein may be used to protect pancreatic islets, pancreatic beta cells, stemcell-derived islets, islet-like clusters, beta-cell organoids, insulin-producing cells, or beta-cell-containing cell preparations from injury. In certain embodiments, injury comprises inflammatory injury, autoimmune injury, alloimmune injury, oxidative injury, metabolic injury, mitochondrial injury, ischemia-reperfusion injury, cytokine -induced injury, activated T-cell-mediated injury, or transplantation-associated injury.

[0131] In certain embodiments, the pancreatic islets are human pancreatic islets. In other embodiments, the pancreatic islets are non-human pancreatic islets, including non-human primate, canine, feline, equine, porcine, or bovine pancreatic islets. In some embodiments, the pancreatic islets comprise cadaveric donor islets, allogeneic islets, autologous islets, xenogeneic islets, stem-cell-derived islets, islet-like clusters, betacell organoids, insulin-producing cells, beta-cell-containing cell preparations, or genetically modified insulinproducing cells.In some embodiments, the islets or beta cells have been exposed to, are exposed to, or are at increased risk of exposure to inflammatory cytokines, including TNF -alpha, IFN-gamma, IL-1 beta, IL-6, IL- 17, or combinations thereof. In other embodiments, the islets or beta cells have been exposed to, are exposed to, or are at increased risk of exposure to activated T cells, islet-reactive T cells, donor-reactive T cells, autoreactive T cells, alloreactive T cells, CD4+ T cells, CD8+ T cells, cytotoxic T cells, natural killer cells, macrophages, autoantibodies, complement, or combinations thereof.

[0132] In certain embodiments, the extracellular vesicle composition preserves or restores glucose-responsive insulin secretion. Preservation or restoration may be measured by increased insulin secretion, increased C-peptide secretion, increased C-peptide release under high-glucose stimulation, improved glucose-stimulated insulin release delta, improved glucose-stimulated insulin release stimulation index, improved response to KC1 stimulation, increased insulin content, increased beta-cell survival, improved islet morphology, or improved mitochondrial function.

[0133] Transplantation Applications

[0134] The compositions disclosed herein may be used before, during, or after transplantation of cells, tissues, organoids, organs, grafts, or engineered constructs. In preferred embodiments, the compositions are used before, during, or after pancreatic islet transplantation, stem-cell-derived islet transplantation, islet-like cluster transplantation, beta-cell organoid transplantation, insulin-producing cell transplantation, or transplantation of beta-cell-containing cell preparations.

[0135] In some embodiments, the compositions are administered to the recipient before transplantation, administered to tire transplant site during transplantation, administered after transplantation, or contacted ex vivo with islets or other transplantable cells prior to transplantation. In some embodiments, the compositions are added to islet culture medium, transport medium, preservation medium, transplant medium, encapsulation medium, biomaterial scaffolds, hydrogels, omental pouch preparations, subcutaneous implant preparations, or organoid culture systems.

[0136] hi certain embodiments, administration improves islet graft survival, improves islet graft function, delays graft rejection, reduces alloimmune rejection, reduces recurrent autoimmune injury, promotes graft tolerance, reduces inflammatory injury, reduces the need for systemic immunosuppression, reduces the need for exogenous insulin administration, or improves durability of insulin independence.

[0137] In some embodiments, the compositions are used with islets, stem-cell-derived islets, beta-cell products, engineered beta cells, organoids, kidney grafts, liver grafts, heart grafts, lung grafts, vascularized composite grafts, skin grafts, tissue-engineered grafts, cell therapy grafts, gene-edited cell products, or other transplantable biological materials.Therapeutic Applications

[0138] In certain embodiments, the extracellular vesicle compositions are used to treat, prevent, delay onset of, slow progression of, or ameliorate Type 1 Diabetes, Type 2 Diabetes associated with islet inflammation, latent autoimmune diabetes in adults, recurrent autoimmunity after islet transplantation, beta-cell dysfunction, allogeneic islet cell rejection, allogeneic islet rejection, inflammatory beta-cell injury, immune-mediated betacell injury, mitochondrial beta-cell dysfunction, or metabolic beta-cell dysfunction.

[0139] In some embodiments, the compositions are used to prevent or treat inflammation, inflammatory disease, autoimmune disease, alloimmune disease, transplant rejection, graft-versus-host disease, fibrosis, fibrotic disease, immune imbalance, immune dysregulation, ischemia-reperfusion injury, mitochondrial dysfunction, organ injury, organoid injury, tissue injury, or immune-mediated tissue damage.

[0140] In certain embodiments, the compositions are administered intravenously, intra-arterially, intraportally, intrapancreatically, intraabdominally, intraperitoneally, subcutaneously, intramuscularly, intranasally, inhalationally, locally to a transplant site, onto the omentum, into an omental pouch, into a subcutaneous implant site, into a hydrogel, into a biomaterial scaffold, or ex vivo to an islet preparation, organoid, cell product, graft, or transplant prior to implantation.

[0141] Engineered Hypoimmune or Immune-Evasive Extracellular Vesicles In certain embodiments, the extracellular vesicles are engineered hypoimmune or immune-evasive extracellular vesicles. Such vesicles may be generated from UC-MSCs, MSCs, or other parental cells that have been genetically, epigenetically, transcriptionally, translationally, or post-translationally modified to reduce immune recognition or enhance immune -evasive properties.

[0142] In some embodiments, engineered extracellular vesicles exhibit reduced or absent presentation of one or more HLA molecules, including HLA class I molecules, HLA class II molecules, HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, HLA -DP, beta-2 microglobulin, CIITA-regulated HLA class II molecules, or combinations thereof. In some embodiments, such reduction is achieved by CRISPR / Cas-mediated genome editing, base editing, prime editing, RNA interference, shRNA, siRNA, antisense oligonucleotides, epigenetic modulation, mRNA transfection, viral transduction, non-viral transfection, protein engineering, culture priming, or combinations thereof.

[0143] In other embodiments, extracellular vesicles are engineered to express, display, carry, or be enriched for one or more immune -evasive molecules, including CD47, PD-L1, HLA-E, HLA-G, CD24, CD55, CD59, CTLA4-Ig, FasL, complement regulatory’ proteins, checkpoint ligands, anti-phagocytic molecules, or functional fragments or variants thereof.

[0144] Such modifications may reduce alloimmune recognition, T-cell activation. NK-cell activation, macrophage-mediated clearance, complement activation, antibody binding, opsonization, inflammatory responses, or rapid clearance, while preserving one or more therapeutic activities of the extracellular vesicles,including immunomodulation, mitochondrial transfer, beta-cell cytoprotection. anti-inflammatory activity, anti-fibrotic activity, tissue repair, and preservation or restoration of glucose-responsive insulin secretion.

[0145] Formulations, Cryoprotectants, and Stabilizers

[0146] The extracellular vesicle compositions may be formulated as pharmaceutical compositions comprising a pharmaceutically acceptable carrier, buffer, excipient, stabilizer, cryoprotectant, lyoprotectant, membrane-protective agent, ice -modulating agent, vitrification agent, drying-protective agent, or diluent.

[0147] In certain embodiments, the extracellular vesicle composition is formulated for refrigerated storage, frozen storage, cryogenic storage, lyophilization, vitrification, spray drying, low-temperature drying, shipment, thawing, or reconstitution after drying. In some embodiments, the composition is formulated for storage at room temperature, at about 25 °C, about +4 °C, about -20 °C, about -80 °C, below -80 °C, about -150 °C, in liquid nitrogen vapor phase, or under cryogenic conditions.

[0148] Suitable cryoprotectants, lyoprotectants, stabilizers, or membrane-protective agents include, without limitation, trehalose, sucrose, mannitol, sorbitol, glycerol, dextran, albumin, polyethylene glycol, dimethyl sulfoxide, hydroxyethyl starch, anti-freeze proteins, ice-binding proteins, anti-freeze glycoproteins, functional fragments or derivatives thereof, peptoids, polypeptoids, polymers, zwitterionic polymers, amino acids, salts, buffers, or combinations thereof.

[0149] In certain embodiments, the stabilizer comprises trehalose, an anti-freeze protein or functional fragment thereof, and / or a peptoid. In some embodiments, the formulation preserves extracellular vesicle membrane integrity, particle concentration, particle-size distribution, surface-marker profile, miRNA cargo, mitochondrial cargo, mitochondrial respiratory function, mitochondrial transfer activity, immunomodulatory potency, anti-inflammatory activity, macrophage-polarizing activity, Treg-expansion activity, Treg-activation activity, T cell-inhibitory activity, anti-fibrotic activity, or beta-cell -protective activity.

[0150] Potency Assays and Qualification Methods

[0151] hi certain embodiments, therapeutically active extracellular vesicle preparations are identified, selected, released, qualified, compared, or ranked using one or more potency assays. Potency attributes may include expansion of CD4+CD25+FOXP3+ regulatory T cells; increase of Helios+ activated regulatory T cells; increase of FOXP3+MKI67+ proliferating regulatory T cells: decrease of CD45RA+ resting regulatory T cells; reduction of CD8+CD45RA+CCR7- effector T cells; reduction of CD4+CD45RA+CCR7- effector T cells; increase of CD8+PD-1+ exhausted T cells; increase of TIM-3+ exhausted T cells; reduction of TNF, IFNG, or EOMES expression; induction of anti-inflammatory macrophage polarization; preservation of glucose-responsive C-peptide secretion in inflamed islets; preservation of glucose-responsive C-peptide secretion in an islet immune attack model; mitochondrial transfer to islet cells; mitochondrial respiratory activity; and presence of an immunomodulatory miRNA signature.In some embodiments, potency assays comprise a human Treg expansion assay, macrophage polarization assay, human islet inflammation model, human islet immune attack model, mitochondrial transfer assay, mitochondrial membrane-potential assay, glucose-stimulated insulin release assay, C-peptide release assay, single-cell RNA sequencing assay, flow-cytometry assay. miRNA profiling assay, or combinations thereof.

[0152] In certain embodiments, an extracellular-vesicle preparation is excluded, deprioritized, rejected, or subjected to additional processing if mitochondrial impairment of the extracellular vesicles reduces or abolishes Treg expansion, Treg activation, T cell inhibition, beta-cell protection, mitochondrial transfer, macrophage polarization, or restoration of glucose-responsive insulin secretion.

[0153] Kits and Articles of Manufacture

[0154] In certain embodiments, the disclosure provides kits comprising an extracellular-vesicle composition described herein and instructions for use. The kit may further comprise a pharmaceutically acceptable carrier, buffer, cryoprotectant, stabilizer, delivery device, infusion set, syringe, vial, cryovial, lyophilized fonnulation, reconstitution solution, transplant medium, islet culture medium, bandage, biomaterial scaffold, hydrogel, or assay reagent.

[0155] In some embodiments, the kit is configured for ex vivo treatment of pancreatic islets or insulinproducing cells before transplantation. In other embodiments, the kit is configured for systemic administration, local administration, subcutaneous administration, intradermal administration, intravenous administration, intraportal administration, intra-arterial administration, intranasal administration, inhalational administration, intramuscular administration, intraperitoneal administration, intrathecal administration, epidural administration, intra-articular administration, intraosseous administration, intrapancreatic administration, intrapancreatic arterial administration, topical administration, infusion pump administration, sustained-release administration, administration to a transplant site, and / or administration to an engrafted organ or tissue.

[0156] Exemplary Embodiments

[0157] In exemplary embodiments, UC-MSCs are cultured under serum-free, xeno-free, cGMP -compliant conditions to generate conditioned medium. The conditioned medium is optionally centrifuged to remove cells and debris, optionally filtered through one or more membranes having a pore size of about 0.2 pm, about 0.45 pm, or a combination thereof, and subjected to tangential flow filtration using a membrane having a pore size of about 5 nm, about 20 mn, to generate an EV-cnrichcd rctcntatc. The EV-cnrichcd rctcntatc comprises extracellular vesicles having a heterogeneous size distribution and containing immunomodulatory microRNAs and functional mitochondria. The EV-enriched retentate stimulates regulatory T cells, reduces effector T cells, induces T-cell exhaustion, polarizes macrophages toward an anti-inflammatory phenotype, transfers functionalmitochondria to pancreatic islet cells, and preserves or restores glucose-responsive C-peptide secretion under inflammatory, immune -mediated, or mitochondrial stress.

[0158] In another exemplary embodiment, pancreatic islets are contacted ex vivo with a UC-MSC EV-enriched fraction before transplantation. The EV-treated islets exhibit improved mitochondrial function, improved glucose-responsive insulin secretion, reduced susceptibility to immune-mediated injury, and improved graft survival after transplantation.

[0159] In another exemplary' embodiment, UC-MSC-derived extracellular vesicles are contacted ex vivo with immune cells from a prospective transplant recipient or therapeutic recipient to determine whether the prospective recipient is a potential responder. Immune cells from the prospective recipient, or from a recipient, may be assessed for regulatory T cell expansion or activation, effector T cell inhibition, induction of T cell exhaustion, reduction of inflammatory or cytotoxic markers, and / or macrophage polarization toward an antiinflammatory M2 or M2-like phenotype. A prospective recipient or a recipient may be classified as a potential responder if the extracellular vesicles induce a regulatory', tolerogenic, anti-inflammatory', or exhausted-effector immune profile relative to untreated prospective recipient or recipient immune cells.

[0160] In another exemplary embodiment, tire extracellular vesicles are engineered hypoimmune extracellular vesicles derived from UC-MSCs modified to reduce HLA presentation and / or express immune-evasive molecules. The engineered extracellular vesicles retain immunomodulatory, mitochondrial-transfer, and beta-cell-protective functions while exhibiting reduced immune recognition, reduced complement activation, reduced macrophage-mediated clearance, or reduced alloimmune activation.

[0161] EXAMPLES

[0162] The following examples are provided for illustration and are not intended to limit the scope of the invention.

[0163] Example 1. Preparation and Characterization of UC-MSC EV-Enriched TFF Retentate UC-MSC conditioned medium is collected after culture of UC-MSCs under serum-free and xeno-free conditions. The conditioned medium is optionally centrifuged, optionally clarified and filtered, and is then processed by tangential flow filtration to obtain an extracellular-vesicle-enriched retentate. The retentate is characterized by dynamic light scattering, nanoparticle tracking analysis, nano-flow cytometry, and surfacemarker analysis. In some embodiments, the retentate comprises particles within a broad nanoscale size range and displays EV-associatcd markers including CD9, CD63, and CD81.

[0164] Example 2. Regulatory T-Cell Expansion and Effector T-Cell Attenuation

[0165] Activated human T cells are contacted with UC-MSC EVs. EV treatment increases CD4+CD25+FOXP3+ regulatory T cells, increases Helios+ activated regulatory T cells, reduces restingCD45RA+ Tregs, reduces CD8+ effector T cells, and increases PD-1+ exhausted CD8+ T cells. In some embodiments, the EV fraction exhibits immunomodulatory activity distinct from cytokine-and-growth-factor fractions of conditioned medium.

[0166] Example 3. Macrophage Polarization

[0167] Human macrophage-like cells are contacted with UC-MSC EVs. EV treatment increases markers associated with anti-inflammatory macrophage polarization, including CD 163, IL- 10, and IL-1R2, and decreases pro-inflammatory mediators including IL-6, TNF, and IFN-gamma.

[0168] Example 4. Human Islet Inflammation Model

[0169] Human pancreatic islets are exposed to inflammatory cytokines including TNF-alpha and IFN-gamma, and are then treated with UC-MSC EVs. Beta-cell function is evaluated by glucose-stimulated insulin release and C-peptide secretion. EV-treated inflamed islets preserve or restore C-peptide release, glucose-stimulated insulin release delta, and stimulation index relative to untreated inflamed islets.

[0170] Example 5. Human Islet Immune Attack Model

[0171] Human pancreatic islets are exposed to inflammatory cytokines and activated human T cells, including T cells stimulated with anti-CD3 / CD28 and interleukin-2. UC-MSC EV treatment protects beta-cell function and preserves glucose-responsive C-peptide secretion. T cells recovered from the co-culture show reduced effector phenotypes and increased exhausted phenotypes.

[0172] Example 6. Single-Cell RNA Sequencing of Immune Reprogramming

[0173] Immune cells exposed to UC-MSC EVs are analyzed by single-cell RNA sequencing. EV treatment increases regulatory T-cell phenotypes and increases expression of markers associated with immune regulation, including TGFB1, IL10, IKZF2, CTLA4, ENTPD1, and NT5E. EV treatment also increases exhaustion markers including PDCD1 / PD-1 and HAVCR2 / TIM-3 and decreases cytotoxic or inflammatory markers including TNF, IFNG, and EOMES.

[0174] Example 7. Mitochondrial Transfer and Mitochondrial Potency

[0175] UC-MSC EVs are labeled with a mitochondrial membrane-potential-dependent dye and contacted with pancreatic islets. Functional mitochondrial signal is transferred to recipient islet cells. In additional embodiments, mitochondrial dysfunction is induced in islets, for example by antimycin A, and EV treatment restores mitochondrial respiratory signal, islet morphology, and glucose-responsive C-peptide secretion. In some embodiments, antimycin A-mediated impairment of EV mitochondrial function reduces or abolishes EV-induced Treg expansion and activation, indicating that mitochondrial integrity is a potency attribute.Example 8. MicroRNA Cargo and Predicted Target Pathways

[0176] MicroRNA cargo of UC-MSC EVs is analyzed by sequencing or quantitative PCR. EVs contain immunomodulatory microRNAs and microRNAs predicted to regulate IL-10, TGF-betal, SMAD2, SMAD3, MRCL CD 163, VEGFA, insulin, and pathways associated with immune tolerance, anti-inflammatory activity, stress adaptation, angiogenesis, beta-cell survival, mitochondrial function, and tissue repair.

[0177] While there have been shown and described fundamental novel features of the invention as applied to the preferred and illustrative embodiments thereof, it will be understood that omissions and substitutions and changes in the fomr and details of the disclosed invention may be made by those skilled in the art without departing from the spirit of the invention. Moreover, as is readily apparent, numerous modifications and changes may readily occur to those skilled in the art. For example, various features and structures of the different embodiments discussed herein may be combined and interchanged. Hence, it is not desired to limit the invention to the exact construction and operation shown and described and, accordingly, all suitable modification equivalents may be resorted to falling within the scope of the invention as claimed. It is the intention, therefore, to be limited only as indicated by the scope of the claims appended hereto.

Claims

CLAIMS1. A composition comprising extracellular vesicles derived from mesenchymal stromal / stem cells (MSCs), wherein the extracellular vesicles comprise exosomes. small extracellular vesicles, medium extracellular vesicles, large extracellular vesicles, or an extracellular-vesicle-enriched fraction, and wherein the extracellular vesicles comprise one or more bioactive cargoes capable of one or more of: preserving, restoring, or enhancing pancreatic islet beta-cell function under inflammatory stress, immune-mediated stress, mitochondrial stress, or a combination thereof; modulating an immune response; stimulating regulatory T cells; inhibiting, reducing, attenuating, or reprogramming effector T cells; reducing inflammation; reducing fibrosis: promoting tissue repair; inducing T-cell exhaustion; transferring functional mitochondria; preserving or restoring cellular bioenergetic function; and protecting a target cell, tissue, organoid, organ, graft, or transplant from inflammatory, autoimmune, alloimmune, metabolic, oxidative, mitochondrial, fibrotic, or immune-mediated injury’.The composition of claim 1, wherein the MSCs comprise human umbilical cord-derived MSCs (UC-MSCs).3 The composition of claim 1 or claim 2, wherein the extracellular vesicles comprise an enriched cargo of immunomodulatory microRNAs.The composition of claim 3, wherein the immunomodulatory microRNAs comprise one or more of let-7a- 5p, let-7c-5p, miR-486-5p, miR-432-5p, miR-125b-5p, miR-25-3p, miR-760, miR-425-5p, miR-320a-3p, miR-142-3p, miR-612, miR-107, miR-21-5p, let-7e-5p, miR-125a, miR-125a-3p, miR-146a-5p, miR-29b- 3p, miR-103-3p, miR-125b-3p, miR-148a-3p, miR-27a-3p, miR-126a-3p, miR-223-3p, miR-92a-3p, miR- 100-5p, miR-130a-3p, miR-16-5p, miR-320b, miR-382-5p, miR-423-5p, miR-494-3p. miR-721. or miR- 193a-3p.5 The composition of claim 1, wherein the extracellular vesicles comprise functional mitochondria, respiring mitochondria, mitochondria-derived vesicles, mitochondrial components, mitochondrial proteins, mitochondrial DNA, mitochondrial RNA, or combinations thereof, capable of being transferred to one or more cells selected from pancreatic islet cells, beta cells, immune cells, T cells, regulatory T cells, effector T cells, macrophages, monocytes, endothelial cells, stromal cells, organoid cells, graft cells, donor cells, recipient cells, transplant cells, or injured cells.6 The composition of claim 5, wherein the functional mitochondria are respiring mitochondria detectable by a mitochondrial membrane-potential-dependent dye.7 Tire composition of claim 1, wherein the extracellular vesicles display one or more cxtraccllular-vcsiclc- associated surface markers selected from CD9, CD63, and CD81.8 The composition of claim 1. wherein the extracellular vesicles have a diameter of about 5 nm to about 200 nm, or about 5 nm to about 450 nm.

9. The composition of claim 1, wherein the extracellular vesicles are present in a tangential flow filtration (TFF) retentate generated from UC-MSC conditioned medium, wherein tire UC-MSC conditioned medium is optionally filtered prior to TFF, and wherein said optional filtration defines an approximate upper size range of particles retained in the TFF retentate.

10. The composition of claim 9, wherein the retentate is enriched for particles retained by a tangential flow filtration membrane having a cutoff of about 5 nm.

11. The composition of claim 1, wherein the MSCs are cultured under serum-free, xeno-free, and / or cGMP- compliant conditions.

12. The composition of claim 1, wherein the extracellular vesicles are formulated for storage at -80 degrees C or below while retaining biological activity.

13. The composition of claim 1, wherein the extracellular vesicles are formulated for refrigerated storage, frozen storage, cryogenic storage, lyophilization, vitrification, spray drying, low -temperature drying, or reconstitution after drying.

14. A method for preserving or restoring glucose-responsive insulin secretion in pancreatic islet beta cells, comprising contacting pancreatic islets with an effective amount of the composition of claim 1.

15. The method of claim 14, wherein the pancreatic islets are inflamed, have been exposed to one or more inflammatory cytokines, exhibit increased expression of one or more HLA molecules, are subject to autoimmune or alloimmune recognition, are exposed to immune-mediated attack, and / or are obtained from, transplanted into, or present in a subject who is positive for one or more islet autoantibodies.

16. Tire method of claim 15, wherein the inflammatory cytokines comprise TNF-alpha, IFN-gamma, IL-1 beta, IL-6. IL- 17, or a combination thereof.

17. The method of claim 14, wherein the pancreatic islets have been exposed to, are exposed to, or are at increased risk of exposure to activated T cells, islet-reactive T cells, donor-reactive T cells, ora combination thereof.

18. The method of claim 17, wherein the T cells recognize, or are activated by, one or more islet beta-cell antigens, pancreatic cell antigens, anti-CD3 / CD28 stimulation, interleukin-2, or a combination thereof.

19. The method of claim 14, wherein the pancreatic islets are exposed to combined inflammatory cytokines and activated T cells.

20. The method of claim 14, wherein preserving or restoring glucose-responsive insulin secretion comprises increasing C-peptide release under high-glucose stimulation relative to untreated inflamed or immune- attackcd islets.

21. Hie method of claim 14, wherein preserving or restoring glucose-responsive insulin secretion comprises improving a glucose-stimulated insulin release delta or a glucose-stimulated insulin release stimulation index.

22. The method of claim 14, w herein the pancreatic islets are human pancreatic islets.

23. The method of claim 14, wherein the pancreatic islets are non-human pancreatic islets comprising nonhuman primate, canine, feline, equine, porcine, or bovine pancreatic islets.

24. The method of claim 14, wherein the pancreatic islets comprise cadaveric donor islets, stem -cell -derived islets, islet-like clusters, beta-cell organoids, insulin-producing cells, or beta-cell-containing cell preparations.

25. A method for protecting pancreatic islets from immune-mediated attack, comprising administering to or contacting the pancreatic islets with an effective amount of MSC-derived extracellular vesicles, wherein the extracellular vesicles reduce beta-cell dysfunction caused by inflammation and / or activated T cells.

26. The method of claim 25, wherein the immune-mediated attack comprises alloimmune rejection, autoimmune attack, inflammatory injury, cytotoxic T-cell attack, or a combination thereof.

27. The method of claim 25, wherein the extracellular vesicles reduce CD8+ CD45RA+ CCR7- effector T cells, reduce CD4+ CD45RA+ CCR7- effector T cells, increase PD-1+ exhausted CD8+ T cells, increase TIM-3+ exhausted T cells, or any combination thereof.

28. Tire method of claim 25, wherein the extracellular vesicles reduce CD4+ PD-1- CD57+ T cells associated with transplant rejection.

29. A method for treating, preventing, or reducing progression of beta-cell dysfunction in a subject, comprising administering to the subject an effective amount of the composition of claim 1.

30. The method of claim 29, wherein the subject has, is at risk of developing, or is undergoing treatment for Type 1 Diabetes, Type 2 Diabetes, latent autoimmune diabetes in adults, recurrent autoimmunity after islet transplantation, or beta-cell dysfunction associated with inflammation.

31. The method of claim 29, wherein the composition is administered before, during, or after pancreatic islet transplantation.

32. The method of claim 31, wherein administration reduces the need for exogenous insulin administration or systemic immunosuppression, improves islet graft survival, improves islet graft function, delays graft rejection, promotes graft tolerance, or any combination thereof.

33. Tire method of claim 29, wherein the composition is administered intravenously, intra-arterially, intraportally, intrapancreatically. intraabdominally, locally to a transplant site, onto the omentum, into an omental pouch, into a subcutaneous implant site, or ex vivo to an islet preparation prior to transplantation.

34. A method for inducing, expanding, activating, or stabilizing regulator}’ T cells (Tregs), comprising contacting T cells with the composition of claim 1, wherein the contacting increases CD4+ CD25+ FOXP3+ regulatory’ T cells, Hclios+ regulatory’ T cells, proliferating FOXP3+ MKI67+ regulatory T cells, or a regulatory T-cell subset co-expressing one or more of TGFB 1, IL10, IKZF2, CTLA4, ENTPD 1, or NT5E.

35. The method of claim 34, wherein the regulatory T cells comprise T cells obtained from a healthy donor or from a subject with Type 1 Diabetes.

36. A method for inducing exhaustion or functional attenuation of effector T cells, comprising contacting T cells with the composition of claim 1, wherein the contacting increases expression of PDCD1 / PD-1, HAVCR2 / TIM-3, or both, and / or decreases expression of TNF, IFNG, EOMES. or any combination thereof.

37. A method for inducing an anti-inflammatory macrophage phenotype, comprising contacting macrophages with the composition of claim 1, wherein expression of one or more of CD163, IL-10, IL-1R2, or MRC1 is increased, and / or expression of one or more of TNF, IFN-gamma, or IL-6 is decreased.

38. A method for transferring functional mitochondria to pancreatic islet cells, comprising contacting pancreatic islets with tire composition of claim 1, wherein functional mitochondria from MSC-derived or UC-MSC-derived extracellular vesicles or tangential flow filtration retentate are transferred to the pancreatic islet cells.

39. The method of claim 38, wherein the pancreatic islet cells have mitochondrial dysfunction or are at risk of mitochondrial dysfunction induced by ischemia, oxidative stress, inflammatory stress, immune-mediated injury, antimycin A, or any combination thereof.

40. The method of claim 38, wherein the transfer of functional mitochondria restores mitochondrial respiratory activity, preserves islet morphology, increases islet survival, or restores glucose-responsive C-peptide secretion.

41. A method for identifying or qualifying a therapeutically active MSC extracellular-vesicle preparation, comprising assaying the preparation for one or more potency attributes selected from: expansion of CD4+ CD25+ FOXP3+ regulatory T cells (Tregs); increase of Helios+ regulatory’ T cells (activated Tregs); decrease of CD45RA+ resting regulatory- T cells (resting Tregs): reduction of CD8+ CD45RA+ CCR7- effector T cells; increase of CD8+ PD-1+ exhausted T cells; induction of an anti-inflammatory macrophage phenotype; preservation of glucose-responsive C-peptide secretion in inflamed islets; preservation of glucose-responsive C-peptide secretion in an islet immune attack model; mitochondrial transfer to islet cells; mitochondrial respiratory' activity; and presence of an immunomodulatory miRNA signature.

42. The method of claim 41, wherein the immunomodulatory signature of the extracellular-vesicle preparation comprises functional mitochondria and / or one or more miRNAs predicted to regulate IL-10, TGF-betal. SMAD2, SMAD3, MRC1 , CD163, VEGFA, insulin, or pathways associated yvith immune tolerance, stress adaptation, angiogenesis, or beta-cell survival.

43. The method of claim 41, further comprising excluding or deprioritizing an extracellular- vesicle preparation in which mitochondrial impairment of the extracellular vesicles reduces or abolishes Treg expansion, Treg activation, beta-cell protection, mitochondrial transfer, or restoration of glucose-responsive insulin secretion.

44. A method for manufacturing a UC-MSC extracellular-vesicle composition, comprising culturing human UC-MSCs under serum-free, xeno-free, and / or cGMP -compliant conditions; collecting conditioned medium: optionally removing cells and debris: optionally filtering the conditioned medium; and concentrating an extracellular-vesicle-enriched retentate by tangential flow filtration.

45. The method of claim 44, wherein the conditioned medium is generated after about 12, 24, 48, 72, or 96 hours of UC-MSC culture.

46. The method of claim 44, wherein the removing of cells and debris comprises centrifugation and the filtering comprises filtration through a membrane of about 0.2 micrometers or about 0.45 micrometers.

47. The method of claim 44, wherein the tangential flow filtration generates a retentate enriched for particles having a diameter of about 5 nm to about 450 nm, about 5 nm to about 300 nm, about 5 nm to about 200 nm, about 30 nm to about 200 nm, about 50 nm to about 250 nm, about 100 nm to about 300 nm, or about 100 nm to about 450 nm.

48. The method of claim 44, further comprising characterizing the extracellular-vesicle-enriched retentate by nanoparticle tracking analysis, dynamic light scattering, nano-flow cytometry, extracellular-vesicle surface marker profiling, miRNA profiling, mitochondrial-function analysis, or any combination thereof.

49. The method of claim 44, further comprising testing the extracellular-vesicle-enriched retentate in a human Treg expansion assay, a macrophage polarization assay, a human islet inflammation model, a human islet immune attack model, a mitochondrial transfer assay, or any combination thereof.

50. An extracellular-vesicle-enriched retentate produced by the method of claim 44.

51. A pharmaceutical composition comprising the composition of claim 1 and a pharmacally acceptable carrier, buffer, excipient, stabilizer, cry oprotectant, or diluent.

52. Use of the composition of claim 1 for the manufacture of a medicament for preserving, restoring, or enhancing pancreatic beta-cell function; protecting pancreatic islets; preserving glucose-responsive insulin secretion; restoring C-peptide secretion; reducing inflammatory, autoimmune, alloimmune, or immune- mediated beta-cell injury; improving tire survival, engraftment, function, or durability of transplanted pancreatic islets or insulin-producing cells; inducing, promoting, or maintaining immune tolerance; reducing or preventing alloimmune rejection; reducing or preventing autoimmune beta-cell destruction; treating, preventing, delaying the onset of, slowing tire progression of, or ameliorating Type 1 Diabetes; treating Type 2 Diabetes associated with islet inflammation or beta-cell dysfunction; treating beta-cell dysfunction associated with inflammatory, metabolic, oxidative, mitochondrial, or immune-mediated injury ; modulating inflammation; treating inflammatory disease; treating fibrosis or fibrotic disease; correcting immune imbalance; suppressing effector T cells; reducing cytotoxic T-cell activity; inducing T- cell exhaustion; expanding, activating, or stabilizing regulatory T cells; polarizing macrophages toward an anti-inflammatory M2 or M2-like phenotype; reducing pro-inflammatory cytokine production; promotingtissue repair; improving transplantation outcomes; reducing the need for systemic immunosuppression; and / or preventing, reducing, or treating graft rejection.

53. The composition of claim 1, wherein the extracellular vesicles are hypoimmune extracellular vesicles engineered to reduce recognition by host immune cells.

54. The composition of claim 53, wherein the hypoimmune extracellular vesicles have reduced or absent presentation of one or more human leukocyte antigen (HLA) molecules.

55. The composition of claim 54, wherein the one or more HLA molecules comprise one or more of HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, HLA-DP, beta-2 microglobulin, or CIITA -regulated HLA class II molecules.

56. The composition of claim 53, wherein the hypoimmune extracellular vesicles are derived from UC-MSCs genetically modified to reduce expression, loading, or surface presentation of one or more HLA class I or HLA class II molecules on the extracellular vesicles.

57. The composition of claim 53, wherein the hypoimmune extracellular vesicles are engineered to express or display one or more immune-evasive molecules.

58. The composition of claim 57, wherein the one or more immune -evasive molecules comprise one or more of CD47, PD-L1, HLA-E, HLA-G, CD24, CD55, CD59, or a functional fragment or variant thereof.

59. The composition of claim 53, wherein the hypoimmune extracellular vesicles are engineered to reduce uptake, clearance, complement activation, antibody binding, NK-cell activation, macrophage-mediated phagocytosis, T-cell activation, or alloimmune recognition.

60. Tire composition of claim 53, wherein the hypoimmune extracellular vesicles are produced from UC- MSCs modified by one or more of CRISPR / Cas-mediated genome editing, RNA interference, shRNA, siRNA, antisense oligonucleotides, epigenetic modulation, transgene expression, mRNA transfection, viral transduction, non-viral transfection, or cell-culture priming.

61. The composition of claim 53, wherein the hypoimmune extracellular vesicles retain one or more functional properties selected from Treg expansion, Treg activation, reduction of effector T cells, induction of T-cell exhaustion, M2 -like macrophage polarization, mitochondrial transfer, preservation of beta-cell viability, and preservation or restoration of glucose-stimulated insulin release or glucose -stimulated C-peptide release.

62. A pharmaceutical composition comprising the composition of claim 53 and a pharmaceutically acceptable carrier, buffer, excipient, stabilizer, cryoprotectant, or diluent.

63. Use of the composition of claim 53 for tire manufacture of a medicament for preserving, restoring, or enhancing pancreatic beta-cell function; protecting pancreatic islets; preserving glucose-responsive insulin secretion; restoring C-peptide secretion; reducing inflammatory, autoimmune, alloimmune, or immune- mediated beta-cell injury’; improving the survival, engraftment, function, or durability of transplanted pancreatic islets or insulin-producing cells: inducing, promoting, or maintaining immune tolerance;reducing or preventing alloimmune rejection; reducing or preventing autoimmune beta-cell destruction; treating, preventing, delaying the onset of, slowing the progression of, or ameliorating Type 1 Diabetes; treating Type 2 Diabetes associated with islet inflammation or beta-cell dysfunction: treating beta-cell dysfunction associated with inflammatory, metabolic, oxidative, mitochondrial, or immune-mediated injury; modulating inflammation; treating inflammatory disease; treating fibrosis or fibrotic disease; correcting immune imbalance; suppressing effector T cells; reducing cytotoxic T-cell activity; inducing T-cell exhaustion; expanding, activating, or stabilizing regulatory' T cells; polarizing macrophages toward an anti-inflammatory M2 or M2-like phenotype; reducing pro-inflammatory’ cytokine production; promoting tissue repair; improving transplantation outcomes; reducing the need for systemic immunosuppression; and / or preventing, reducing, or treating graft rejection.